细胞和基因疗法低温运输物流市场－全球产业规模、份额、趋势、机会和预测：组成部分、服务内容、温度范围、终端用户、地区和竞争格局（2021-2031）

全球细胞和基因疗法低温运输物流市场预计将从 2025 年的 20.2 亿美元成长到 2031 年的 44.7 亿美元，复合年增长率达 14.15%。

该行业涵盖专门从事治疗性生物材料温控处理、储存和运输的供应链服务。这些物流解决方案对于维持对温度和时间敏感的细胞产品的疗效至关重要，这些产品通常需要在整个运输过程中保持低温状态。推动该市场发展的主要因素是临床开发平臺的快速扩张以及由此带来的监管核准数量的增加，这促使人们对安全的全球分销网络的需求日益增长。根据国际细胞与基因治疗学会 (ISCT) 的报告，到 2024 年，全球治疗方法研发管线将扩展至 3,063 种疗法，这将显着增加对这些新兴治疗方法的专业物流支持的需求。

儘管市场呈现上升趋势，但在复杂的国际价值链中维持严格的温度稳定性方面，仍面临巨大的挑战。对超低温的需求增加了因温度波动而导致产品损失的风险，尤其是在关键的「最后一公里」配送环节。此外，某些地区基础设施的匮乏可能会阻碍低温运输的连续性，使这些高价值治疗药物的分销更加复杂，并阻碍市场在全球范围内的进一步扩张。

市场驱动因素

全球对生物製药研发的投资和资金筹措不断增长，透过资助不断扩大的临床项目及其物流需求，推动了市场成长。这笔资金的涌入使开发商能够外包关键的高端温控供应链服务，从而保护敏感的生物资产。根据 BioSpace 2024 年 10 月发表的一篇报导《细胞和基因疗法投资在充满挑战的一年后增长》的文章，该行业在 2024 年上半年吸引了 109 亿美元的投资。这些资金支持着广泛的研究，并推动了对专业处理的需求。例如，Cryoport 报告称，截至 2024 年 9 月 30 日，其支持的全球临床试验数量创下历史新高，达到 691 项，凸显了这笔资金推动的强劲研发势头。

此外，随着细胞和基因疗法的商业化和监管核准加速推进，业界的重点正从临床用药转向大规模商业分销。随着治疗方法的获批，需要扩展物流网络，以确保全球患者都能获得治疗，同时遵守严格的标准。向商业化阶段的过渡需要严密的低温运输基础设施，以防止温度波动，从而避免影响高价值疗法的疗效。根据《世界快递》（World Courier）于2024年10月发布的《2024年第三季细胞和基因疗法研发管线关键洞察》报告，目前全球已有134种核准的细胞和基因疗法。不断增长的商业化产品数量需要一个能够满足超低温要求的强大分销网络。

市场挑战

全球细胞和基因疗法低温运输物流市场面临的主要障碍之一是难以在日益复杂的国际价值链中维持严格的温度稳定性。这些高价值疗法通常需要超低温冷冻环境，运输过程中温度波动或基础设施故障都可能导致产品不可逆转的损失。在低温运输基础设施薄弱或最后一公里配送时间长的地区，这种脆弱性尤其突出，严重阻碍了市场进入和商业性扩张。

物流方面的脆弱性因其行业的全球规模而进一步加剧。根据再生医学联盟（Alliance for Regenerative Medicine）预测，到2025年，全球细胞和基因治疗收入的约35%将来自美国以外的市场。这项数据表明，该行业相当一部分经济价值严重依赖跨境运输。因此，不同地区气温波动带来的风险会对开发商造成财务上的不确定性，迫使他们限制市场扩大策略，并直接减缓全球物流业的整体成长。

市场趋势

基于云端的细胞编配平台正在透过以整合的数位生态系统取代人工追踪方式，从而变革整个产业。随着自体疗法的扩展，製造商需要即时掌握从静脉到静脉的整个过程，以确保复杂工作流程中的身份链完整性。这种数位转型有效地连接了製造地和临床中心，减少了人为错误，并简化了白血球分离术和输注的安排。根据TrakCel公司于2024年11月发布的报告《TrakCel树立行业标竿》，该公司的编配平台已被选中支持2024年已通过核准或预计核准的七种自体或匹配异体细胞治疗产品中的五种。

此外，随着生物製药公司寻求降低高价值商业产品分销相关风险，将业务策略外包给专业的利基物流供应商变得至关重要。与标准药品运输不同，细胞和基因疗法 (CGT) 物流需要专门的基础设施，包括低温杜瓦罐的车队管理以及严格遵守再生医学监管标准。为了确保产品完整性，研发人员越来越多地选择与具备专业能力的供应商合作，而不是与普通货运公司合作。根据 Cryoport 公司于 2025 年 3 月发布的《2024 年第四季及全年财务业绩报告》，其为已获商业已通过核准的细胞和基因治疗产品提供支持的收入将在 2024 年达到 2,600 万美元，年成长 20%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 细胞与基因疗法全球低温运输物流市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按组件分类（低温运输容器、低温储存冷冻冷冻库、超低温冷冻库、低温运输管理系统、运输和储存媒体、低温包装套件、其他）
  • 依提供的服务（运输、仓储、包装）
  • 透过交通方式（航空、陆路、海运）
  • 依温度范围（超低温、冷藏、室温、其他）
  • 依最终用户（製药/生技公司、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美细胞与基因治疗低温运输物流市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲细胞与基因治疗低温运输物流市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区细胞与基因治疗低温运输物流市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲细胞与基因治疗低温运输物流市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美细胞与基因治疗低温运输物流市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球细胞与基因治疗低温运输物流市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Cencora, Inc.
• United Parcel Service, Inc.
• Catalent, Inc.
• BioLife Solutions, Inc.
• Cryoport System LLC.
• Atelerix Ltd.
• Life Science Group Ltd
• Yourway Biopharma Services Company
• Bertelsmann SE & Co. KGaA
• NMDP BioTherapies

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Cell & Gene Therapy Cold Chain Logistics Market is projected to expand from USD 2.02 Billion in 2025 to USD 4.47 Billion by 2031, registering a CAGR of 14.15%. This sector encompasses specialized supply chain services focused on the temperature-controlled handling, storage, and transport of therapeutic biological materials. These logistics solutions are vital for maintaining the efficacy of temperature-sensitive and time-critical cellular products, which frequently demand cryogenic conditions throughout transit. A major factor driving this market is the rapid growth of the clinical development pipeline and the resulting rise in regulatory approvals, creating a need for secure global distribution networks. As reported by the International Society for Cell & Gene Therapy, the global sector pipeline expanded to 3,063 therapies in 2024, generating significant demand for specialized logistical support for these emerging treatments.

Despite this upward trajectory, the market encounters substantial difficulties in maintaining strict temperature stability across intricate international supply chains. The necessity for ultra-low temperatures poses a high risk of product loss due to potential temperature excursions, especially during the critical last-mile delivery stage. Additionally, infrastructure deficiencies in specific geographic areas can interrupt the cold chain's continuity, complicating the distribution of these high-value therapeutics and potentially hindering the market's broader global expansion.

Market Driver

The rise in global investments and funding for biopharmaceutical R&D drives market growth by financing expanded clinical programs and their logistical requirements. Substantial capital inflows allow developers to outsource essential, premium temperature-controlled supply chain services to protect sensitive biological assets. According to an October 2024 BioSpace article titled 'Cell and Gene Therapy Investment Ticks Up After Hard Few Years', the sector secured $10.9 billion in investment during the first half of 2024. This funding supports extensive research and drives demand for specialized handling; for instance, Cryoport, Inc. reported supporting a record 691 global clinical trials as of September 30, 2024, highlighting the intense development activity driven by this capital.

Furthermore, the accelerating commercialization and regulatory approval of cell and gene therapies are shifting the industry's focus from clinical shipments to high-volume commercial distribution. As therapies receive authorization, logistics networks must expand to guarantee global patient access while adhering to strict standards. Transitioning to commercial stages requires rigorous cold chain infrastructure to prevent temperature excursions that could compromise high-value treatments. According to World Courier's 'CGT pipeline key insights for 2024 Q3' published in October 2024, there are now 134 cell and gene therapies approved globally. This growing number of commercial products demands robust distribution networks capable of managing ultra-low temperature requirements.

Market Challenge

The primary obstacle hindering the Global Cell & Gene Therapy Cold Chain Logistics Market is the complexity of maintaining rigorous temperature stability throughout increasingly intricate international supply chains. Because these high-value therapeutics frequently demand ultra-low cryogenic temperatures, any thermal excursion or infrastructure failure during transit can lead to irreversible product loss. This fragility is especially damaging when distributing to regions with unreliable cold chain capabilities or extended last-mile delivery durations, serving as a significant barrier to market accessibility and commercial scaling.

The consequences of this logistical vulnerability are greatly intensified by the industry's global scope. According to the Alliance for Regenerative Medicine, approximately 35 percent of global revenue from cell and gene therapy in 2025 originated from markets outside the United States. This statistic highlights that a significant portion of the sector's economic value depends heavily on cross-border transport. As a result, the risk of temperature deviations across diverse geographic landscapes generates financial uncertainty for developers, compelling them to restrict market expansion strategies and directly slowing the broader growth of the global logistics sector.

Market Trends

The deployment of cloud-based cell orchestration platforms is transforming the sector by substituting manual tracking methods with integrated digital ecosystems. As autologous therapies scale, manufacturers need real-time vein-to-vein visibility to guarantee the preservation of the Chain of Identity across complex workflows. This digital transition reduces human error and streamlines the scheduling of leukapheresis and infusion, effectively connecting manufacturing sites with clinical centers. According to TrakCel's 'TrakCel Sets New Standards' announcement in November 2024, the company's orchestration platform was chosen to support five out of the seven autologous or matched allogeneic cell therapy products approved or anticipated for approval in 2024.

Additionally, strategic outsourcing to specialized niche logistics providers is becoming essential as biopharmaceutical companies aim to reduce the risks associated with distributing high-value commercial products. Unlike standard pharmaceutical shipping, CGT logistics require dedicated infrastructure, such as fleet management for cryogenic dewars and strict compliance with regenerative medicine regulatory standards. Developers are increasingly collaborating with vendors that offer purpose-built capabilities rather than generalist freight forwarders to ensure product integrity. According to Cryoport, Inc.'s 'Fourth Quarter and Full Year 2024 Financial Results' from March 2025, revenue from supporting commercially approved cell and gene therapies grew to $26 million in 2024, representing a 20 percent year-over-year increase.

Key Market Players

• Cencora, Inc.
• United Parcel Service, Inc.
• Catalent, Inc.
• BioLife Solutions, Inc.
• Cryoport System LLC.
• Atelerix Ltd.
• Life Science Group Ltd
• Yourway Biopharma Services Company
• Bertelsmann SE & Co. KGaA
• NMDP BioTherapies

Report Scope

In this report, the Global Cell & Gene Therapy Cold Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy Cold Chain Logistics Market, By Component

• Cryogenic Shippers
• Cryogenic Storage Freezers
• Ultra Low Freezers
• Cold Chain Management Systems
• Shipment and Storage Medium
• Cryogenic Packout Kits
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By Services Offered

• Transportation
• Storage
• Packaging

Cell & Gene Therapy Cold Chain Logistics Market, By Mode of Transportation

• Air
• Ground
• Water

Cell & Gene Therapy Cold Chain Logistics Market, By Holding Temperature Range

• Cryogenic
• Refrigerated
• Ambient
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

Cell & Gene Therapy Cold Chain Logistics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Cold Chain Logistics Market.

Available Customizations:

Global Cell & Gene Therapy Cold Chain Logistics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others)
  • 5.2.2. By Services Offered (Transportation, Storage, Packaging)
  • 5.2.3. By Mode of Transportation (Air, Ground, Water)
  • 5.2.4. By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others)
  • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Services Offered
  • 6.2.3. By Mode of Transportation
  • 6.2.4. By Holding Temperature Range
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Services Offered
      • 6.3.1.2.3. By Mode of Transportation
      • 6.3.1.2.4. By Holding Temperature Range
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Services Offered
      • 6.3.2.2.3. By Mode of Transportation
      • 6.3.2.2.4. By Holding Temperature Range
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Services Offered
      • 6.3.3.2.3. By Mode of Transportation
      • 6.3.3.2.4. By Holding Temperature Range
      • 6.3.3.2.5. By End User

7. Europe Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Services Offered
  • 7.2.3. By Mode of Transportation
  • 7.2.4. By Holding Temperature Range
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Services Offered
      • 7.3.1.2.3. By Mode of Transportation
      • 7.3.1.2.4. By Holding Temperature Range
      • 7.3.1.2.5. By End User
  • 7.3.2. France Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Services Offered
      • 7.3.2.2.3. By Mode of Transportation
      • 7.3.2.2.4. By Holding Temperature Range
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Services Offered
      • 7.3.3.2.3. By Mode of Transportation
      • 7.3.3.2.4. By Holding Temperature Range
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Services Offered
      • 7.3.4.2.3. By Mode of Transportation
      • 7.3.4.2.4. By Holding Temperature Range
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Services Offered
      • 7.3.5.2.3. By Mode of Transportation
      • 7.3.5.2.4. By Holding Temperature Range
      • 7.3.5.2.5. By End User

8. Asia Pacific Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Services Offered
  • 8.2.3. By Mode of Transportation
  • 8.2.4. By Holding Temperature Range
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Services Offered
      • 8.3.1.2.3. By Mode of Transportation
      • 8.3.1.2.4. By Holding Temperature Range
      • 8.3.1.2.5. By End User
  • 8.3.2. India Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Services Offered
      • 8.3.2.2.3. By Mode of Transportation
      • 8.3.2.2.4. By Holding Temperature Range
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Services Offered
      • 8.3.3.2.3. By Mode of Transportation
      • 8.3.3.2.4. By Holding Temperature Range
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Services Offered
      • 8.3.4.2.3. By Mode of Transportation
      • 8.3.4.2.4. By Holding Temperature Range
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Services Offered
      • 8.3.5.2.3. By Mode of Transportation
      • 8.3.5.2.4. By Holding Temperature Range
      • 8.3.5.2.5. By End User

9. Middle East & Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Services Offered
  • 9.2.3. By Mode of Transportation
  • 9.2.4. By Holding Temperature Range
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Services Offered
      • 9.3.1.2.3. By Mode of Transportation
      • 9.3.1.2.4. By Holding Temperature Range
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Services Offered
      • 9.3.2.2.3. By Mode of Transportation
      • 9.3.2.2.4. By Holding Temperature Range
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Services Offered
      • 9.3.3.2.3. By Mode of Transportation
      • 9.3.3.2.4. By Holding Temperature Range
      • 9.3.3.2.5. By End User

10. South America Cell & Gene Therapy Cold Chain Logistics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Services Offered
  • 10.2.3. By Mode of Transportation
  • 10.2.4. By Holding Temperature Range
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Services Offered
      • 10.3.1.2.3. By Mode of Transportation
      • 10.3.1.2.4. By Holding Temperature Range
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Services Offered
      • 10.3.2.2.3. By Mode of Transportation
      • 10.3.2.2.4. By Holding Temperature Range
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Cell & Gene Therapy Cold Chain Logistics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Services Offered
      • 10.3.3.2.3. By Mode of Transportation
      • 10.3.3.2.4. By Holding Temperature Range
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell & Gene Therapy Cold Chain Logistics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cencora, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. United Parcel Service, Inc.
• 15.3. Catalent, Inc.
• 15.4. BioLife Solutions, Inc.
• 15.5. Cryoport System LLC.
• 15.6. Atelerix Ltd.
• 15.7. Life Science Group Ltd
• 15.8. Yourway Biopharma Services Company
• 15.9. Bertelsmann SE & Co. KGaA
• 15.10. NMDP BioTherapies

16. Strategic Recommendations

17. About Us & Disclaimer